Novo Nordisk A/S
SOLID COMPOSITIONS FOR ORAL ADMINISTRATION

Last updated:

Abstract:

The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor.

Status:
Application
Type:

Utility

Filling date:

11 Jun 2018

Issue date:

14 May 2020